(NASDAQ: CNSY) Cerenome's forecast annual revenue growth rate of 118.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Cerenome's revenue in 2026 is $4,203,000.On average, 6 Wall Street analysts forecast CNSY's revenue for 2026 to be $46,797,628, with the lowest CNSY revenue forecast at $22,313,498, and the highest CNSY revenue forecast at $83,895,715. On average, 6 Wall Street analysts forecast CNSY's revenue for 2027 to be $148,179,839, with the lowest CNSY revenue forecast at $74,378,325, and the highest CNSY revenue forecast at $223,134,975.
In 2028, CNSY is forecast to generate $350,762,109 in revenue, with the lowest revenue forecast at $298,773,178 and the highest revenue forecast at $406,424,419.